[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL265981A - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
IL265981A
IL265981A IL265981A IL26598119A IL265981A IL 265981 A IL265981 A IL 265981A IL 265981 A IL265981 A IL 265981A IL 26598119 A IL26598119 A IL 26598119A IL 265981 A IL265981 A IL 265981A
Authority
IL
Israel
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
IL265981A
Other languages
Hebrew (he)
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of IL265981A publication Critical patent/IL265981A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21104Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL265981A 2016-10-13 2019-04-11 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy IL265981A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (1)

Publication Number Publication Date
IL265981A true IL265981A (en) 2019-06-30

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265981A IL265981A (en) 2016-10-13 2019-04-11 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (18)

Country Link
EP (1) EP3525798A4 (en)
JP (1) JP6893554B2 (en)
KR (1) KR102348939B1 (en)
CN (2) CN116726163A (en)
AU (1) AU2017342428B2 (en)
BR (1) BR112019007426A2 (en)
CA (2) CA3210384A1 (en)
CL (2) CL2019000909A1 (en)
GE (1) GEP20247587B (en)
IL (1) IL265981A (en)
JO (1) JOP20190068A1 (en)
MA (1) MA46541A (en)
MX (1) MX2019004074A (en)
PH (1) PH12019500711A1 (en)
SG (1) SG11201902941UA (en)
UA (1) UA126908C2 (en)
WO (1) WO2018071701A1 (en)
ZA (1) ZA201902933B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (en) * 2020-03-19 2020-07-17 长春市儿童医院 Glomerular lobular nephropathy modeling method
CN115215937B (en) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
EP4444758A2 (en) 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN117016486B (en) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 Animal model construction method for IgA nephropathy combined membranous nephropathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024996T2 (en) * 2003-05-12 2016-01-28 Helion Biotech Aps Antibodies to masp-2
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
MX344322B (en) * 2009-10-16 2016-12-13 Omeros Corp Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation.
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
KR20180072851A (en) * 2011-04-08 2018-06-29 유니버시티 오브 레스터 Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2012250627B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement acitivation
ES2964340T3 (en) * 2013-03-15 2024-04-05 Omeros Corp Methods for generating antibodies carrying bioactive peptides and compositions comprising the same
NZ757986A (en) * 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
EA201891570A1 (en) * 2016-01-05 2018-12-28 Юниверсити Оф Лестер METHOD OF SUPPORTING FIBROSIS IN NECESSARY IN THIS SUBJECT
JOP20170170B1 (en) * 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number Publication date
ZA201902933B (en) 2023-05-31
CN110177557A (en) 2019-08-27
MX2019004074A (en) 2019-06-10
CA3039927A1 (en) 2018-04-19
JP6893554B2 (en) 2021-06-23
SG11201902941UA (en) 2019-05-30
JP2019534271A (en) 2019-11-28
AU2017342428B2 (en) 2021-02-04
JOP20190068A1 (en) 2019-04-01
CA3210384A1 (en) 2018-04-19
KR102348939B1 (en) 2022-01-12
CN116726163A (en) 2023-09-12
EP3525798A1 (en) 2019-08-21
EP3525798A4 (en) 2020-07-08
CL2019000909A1 (en) 2019-06-14
CL2019003485A1 (en) 2020-04-13
KR20190063475A (en) 2019-06-07
NZ753260A (en) 2021-11-26
MA46541A (en) 2019-08-21
PH12019500711A1 (en) 2019-11-18
WO2018071701A1 (en) 2018-04-19
AU2017342428A1 (en) 2019-05-23
GEP20247587B (en) 2024-01-25
CA3039927C (en) 2023-10-10
UA126908C2 (en) 2023-02-22
BR112019007426A2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
SG11201609238VA (en) Binding affinity prediction system and method
HK1250918A1 (en) Egfr-directed car therapy for glioblastoma
PT3099946T (en) Connecting means and method for connecting two parts
HUE053370T2 (en) Method for mode switching
HK1254988A1 (en) Connecting means and method for connecting two components
ZA201702173B (en) Sorbent for binding metal and production thereof
IL264641A (en) Acetyl-leucine for use in treating neurodegenerative diseases
ZA201902933B (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
PL2960001T3 (en) Welding system and communication method for welding system
TWI560635B (en) System and method for rating and selecting models
HK1231556A1 (en) Predictive method for determining tissual radiosensitivity
IL260347A (en) Therapeutic anti-cd9 antibody
SG11201607485PA (en) A method and system for enabling a payment
ZA201805743B (en) Hla-b57 open conformers
HK1244314A1 (en) A method for predicting the risk of obesity in a subject
HUE049274T2 (en) Method and control unit for the control of a vehicle, in particular of a rail vehicle
GB201609084D0 (en) System for use in bioprocessing
GB201516617D0 (en) Verification for payment transations
IL231685A (en) System and method for predictive buffering and network shaping
IL231278A0 (en) System for assistance in transition between standing and sitting and standing
SG10201603667WA (en) Methods and systems for making payments
GB201406223D0 (en) Method and system for facilitating a transaction
SG11201705576YA (en) Methods for gel reduction in polyolefins
PL3081725T3 (en) Intermediate fitting for closure system
HK1222029A1 (en) Method and device for transaction control